

ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2023 to 12/31/2023)
MedStar Georgetown University Hospital



**MedStar Georgetown
University Hospital**

Gram Negative Organisms

	Number of Isolates	Percent Susceptible																		
		Ampicillin***	Ampicillin/sulbactam	Aztreonam	Cefazolin (Systemic ^a)	Cefazolin (Urine ^b)	Cefepime	Cefotaxime	Ciprofloxacin	ESBL (Negative)	Gentamicin***	Levofoxacin	Meropenem	Nitrofurantoin*	Piperacillintazobactam	Tetrahymycin***	Trimethoprim/Sulfa			
Acinetobacter baumannii	56	74	-	39	-	-	58	60	43	46	-	49	-	-	-	-	70	-		
Enterobacter cloacae	347	100	0	0	75	-	82	73	73	76	-	94	-	98	47	82	100	100	86	
Escherichia coli	1019	100	39	47	76	54	69	77	75	76	54	75	86	-	98	97	90	60	82	61
Klebsiella pneumoniae ssp pneumoniae	651	100	0	59	76	61	76	78	74	75	49	58	92	-	96	49	80	71	88	72
Morganella morganii	81	100	0	31	98	-	-	100	90	96	81	-	88	-	100	-	99	46	92	78
Proteus mirabilis	322	95	77	87	94	0	82	92	93	90	77	-	91	-	-	0	99	0	89	80
Pseudomonas aeruginosa	777	99	-	-	72	-	-	85	86	-	70	-	-	-	84	-	79	-	97	-
Serratia marcescens	57	98	0	0	93	-	-	93	91	84	90	-	93	-	100	0	97	-	84	-
Stenotrophomonas maltophilia	147	-	-	-	-	-	-	-	33	-	-	-	-	70	-	-	-	-	-	99



**MedStar Georgetown
University Hospital**

Gram Positive Organisms

	Number of Isolates	Percent Susceptible																	
		Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non-meningitis)	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Fluorquinolone	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Penicillin (non-meningitis)	Tetracycline	Trimethoprim/Sulfa	Vancomycin		
Enterococcus faecalis	595	100	-	-	-	97	-	96	-	80	-	-	-	-	23	-	97	-	-
Enterococcus faecium	268	-	-	-	-	93	-	-	91	-	-	-	-	-	-	-	-	-	35
Methicillin resistant Staphylococcus aureus (MRSA)***	370	-	-	-	54	98	82	17	100	-	-	0	-	-	73	79	100	-	-
Methicillin sensitive Staphylococcus aureus (MSSA)	547	-	-	-	78	100	97	61	100	-	-	100	-	-	92	96	100	-	-
Staphylococcus coagulase-negative	601	-	-	-	70	100	94	-	100	-	-	48	-	-	-	-	-	100	-
Streptococcus pneumoniae**	64	-	98	100	86	-	-	67	100	98	-	-	72	95	79	79	100	-	-

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(*) Tested on urine isolate only (** Due to low incidence, organism incidence consists of totals from MGUH, and MWHC combined

(***) MRSA rate of the institution was 40% (****) Based on CLSI M100-32nd Ed breakpoints

^a Cefazolin (systemic), MIC ≤ 2 µg/mL susceptible for infections other than uncomplicated UTIs

^b Cefazolin (urine), MIC ≤ 16 µg/mL susceptible